Solventum Co. (NYSE:SOLV) Position Increased by Clifford Capital Partners LLC

Clifford Capital Partners LLC boosted its position in shares of Solventum Co. (NYSE:SOLV) by 22.6% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 279,479 shares of the company’s stock after acquiring an additional 51,533 shares during the period. Solventum comprises 3.9% of Clifford Capital Partners LLC’s investment portfolio, making the stock its 5th biggest holding. Clifford Capital Partners LLC owned about 0.16% of Solventum worth $19,485,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of SOLV. Price T Rowe Associates Inc. MD acquired a new stake in Solventum during the first quarter worth approximately $5,889,000. LRI Investments LLC acquired a new position in Solventum in the first quarter valued at $43,000. EverSource Wealth Advisors LLC acquired a new position in Solventum in the first quarter valued at $30,000. GAMMA Investing LLC acquired a new stake in shares of Solventum during the second quarter worth about $74,000. Finally, Massmutual Trust Co. FSB ADV acquired a new position in Solventum in the 2nd quarter valued at about $34,000.

Solventum Price Performance

Shares of Solventum stock opened at $71.50 on Wednesday. The company has a 50-day moving average of $70.51 and a two-hundred day moving average of $62.40. Solventum Co. has a 12-month low of $47.16 and a 12-month high of $96.05. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Piper Sandler boosted their target price on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a report on Friday, November 8th. The Goldman Sachs Group boosted their price objective on shares of Solventum from $48.00 to $54.00 and gave the company a “sell” rating in a research note on Monday, August 12th. Wolfe Research began coverage on shares of Solventum in a research note on Thursday, September 26th. They issued a “peer perform” rating for the company. Stifel Nicolaus started coverage on shares of Solventum in a research note on Tuesday, October 8th. They set a “buy” rating and a $82.00 price target on the stock. Finally, Morgan Stanley raised their price objective on shares of Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, Solventum presently has a consensus rating of “Hold” and a consensus target price of $68.00.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.